Lobbying World: Crapo alums reunite as Quickel joins Hollier & Associates

Mike Quickel, former policy director and longtime tax and budget policy adviser to Sen. Mike Crapo (R-Idaho), has joined Hollier & Associates as a partner. The move reunites Quickel with Will Hollier, Crapo’s former chief of staff and founder of the lobbying firm.

Ed Hill is joining Forbes Tate Partners as a partner in the firm’s government relations practice. Hill was most recently senior vice president and head of government affairs for the Bank Policy Institute, a financial services industry lobbying and advocacy group.

Wendy Sammons-Jackon is joining the federal government relations team at Cornerstone Government Affairs. A retired U.S. Army colonel, she was most recently the deputy principal assistant for research and technology at the U.S. Army Medical Research and Development Command.

Tiber Creek Group has hired Nikole Burroughs as a partner. Burroughs was most recently deputy chief of staff in the U.S. Agency for International Development.

Katie Mahoney is joining the Healthcare Leadership Council (HLC) as executive vice president and chief policy officer. She comes to the HLC from the U.S. Chamber of Commerce, where she was most recently vice president of health policy.

Will Anderson is returning to Business Roundtable as vice president of corporate governance. He was most recently staff director of the House Financial Services Committee’s Subcommittee on Capital Markets.

Sarah Puro is joining Alliance for Automotive Innovation as vice president of safety and technology policy. Puro was most recently a senior adviser to National Transportation Safety Board Chair Jennifer Homendy.

Patrick Kane has joined the Motion Picture Association as vice president of digital strategy. He was previously head of digital for the British Embassy.

Lo Isidro has joined Narrative Strategies as a senior director. He was most recently a senior director at Real Chemistry, and he is a Stand Together, Americans for Prosperity and Capitol Hill alum.

Gilead Sciences Chair and CEO Daniel O’Day is the new chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors. O’Day succeeds Novartis CEO Vasant Narasimhan as board chair. Pfizer Chair and CEO Albert Bourla was named board chair-elect, and Paul Hudson, CEO of Sanofi, will serve as treasurer.